Amgen to Pay $762 Million Settlement on Drug Marketing

Tuesday, 18 Dec 2012 05:58 PM

 

  Comment  |
   Contact  |
  Print   |
    A   A  
  Copy Shortlink

Amgen will pay $762 million to settle litigation that accuses the drugmaker of marketing the anemia drug Aranesp for unapproved uses.

A law firm involved in the case says the Thousand Oaks, Calif., company will pay a $612 million civil settlement, $136 million in criminal fines and a $14 million forfeiture.

Amgen Inc. says it entered a conditional guilty plea to a misdemeanor count of misbranding Aranesp. The company took a $780 million charge last year for a possible settlement.

Amgen develops biologic medicines, or drugs produced by living cells rather than by mixing chemicals. Its settlement marks the latest between the U.S. Department of Justice and a drugmaker over improper marketing allegations.

Doctors can prescribe drugs for unapproved uses, but companies aren't allowed to market drugs for those uses.

© Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

  Comment  |
   Contact  |
  Print   |
  Copy Shortlink
Around the Web

Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 

You May Also Like
Around the Web

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved